Cargando…

Refined characterization of circulating tumor DNA through biological feature integration

Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell-free DNA (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent studies have been focused on understanding the non-random fragmentation pattern of cfDNA. These studies have investigated frag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markus, Havell, Chandrananda, Dineika, Moore, Elizabeth, Mouliere, Florent, Morris, James, Brenton, James D., Smith, Christopher G., Rosenfeld, Nitzan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816939/ https://www.ncbi.nlm.nih.gov/pubmed/35121756 http://dx.doi.org/10.1038/s41598-022-05606-z

Ejemplares similares

Detection of cell‐free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients
por: Mouliere, Florent, et al.
Publicado: (2018)

Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations
por: Nygård, Lotte, et al.
Publicado: (2020)

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
por: Hudecova, Irena, et al.
Publicado: (2022)

Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients
por: Risberg, Bente, et al.
Publicado: (2018)

Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
por: Crispin-Ortuzar, Mireia, et al.
Publicado: (2023)

Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients
por: Mouliere, Florent, et al.
Publicado: (2021)

High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA
por: Chandrananda, Dineika, et al.
Publicado: (2015)

A hitchhiker’s guide to cell-free DNA biology
por: Mouliere, Florent
Publicado: (2022)

The landscape of cell-free mitochondrial DNA in liquid biopsy for cancer detection
por: van der Pol, Ymke, et al.
Publicado: (2023)

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
por: Tsui, Dana Wai Yi, et al.
Publicado: (2018)

Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors
por: Smith, Christopher G., et al.
Publicado: (2020)

Cell-free DNA technologies for the analysis of brain cancer
por: Mair, Richard, et al.
Publicado: (2021)

High Fragmentation Characterizes Tumour-Derived Circulating DNA
por: Mouliere, Florent, et al.
Publicado: (2011)

Investigating and Correcting Plasma DNA Sequencing Coverage Bias to Enhance Aneuploidy Discovery
por: Chandrananda, Dineika, et al.
Publicado: (2014)

Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts
por: Thierry, Alain R., et al.
Publicado: (2010)

Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
por: Gill, Andrew B., et al.
Publicado: (2020)

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer
por: Patel, K. M., et al.
Publicado: (2017)

Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics
por: Lv, Jiawei, et al.
Publicado: (2022)

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
por: Parkinson, Christine A., et al.
Publicado: (2016)

REFINED-CNN framework for survival prediction with high-dimensional features
por: Bazgir, Omid, et al.
Publicado: (2023)

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models
por: Sauer, Carolin M, et al.
Publicado: (2022)

Integrating Climate Change Resilience Features into the Incremental Refinement of an Existing Marine Park
por: Davies, Harriet N., et al.
Publicado: (2016)

CVE: an R package for interactive variant prioritisation in precision oncology
por: Mock, Andreas, et al.
Publicado: (2017)

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
por: Ahlborn, Lise Barlebo, et al.
Publicado: (2018)

Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
por: Solar Vasconcelos, Joao Paulo, et al.
Publicado: (2022)

Addressing cellular heterogeneity in tumor and circulation for refined prognostication
por: Lim, Su Bin, et al.
Publicado: (2019)

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
por: Prat, Aleix, et al.
Publicado: (2023)

Feature Refine Network for Salient Object Detection
por: Yang, Jiejun, et al.
Publicado: (2022)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Refined Wirtinger-type integral inequality
por: Zhang, Liansheng, et al.
Publicado: (2018)

Petroleum refining : technology and economics /
por: Gary, James H., 1921-
Publicado: (2007)

Refining epigenetic prediction of chronological and biological age
por: Bernabeu, Elena, et al.
Publicado: (2023)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

Engineering exosomes as refined biological nanoplatforms for drug delivery
por: Luan, Xin, et al.
Publicado: (2017)

Remove, Refine, Reduce: Cell Death in Biological Systems
por: Krüger, Marcus
Publicado: (2023)

The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma
por: Yuwono, Nicole Laurencia, et al.
Publicado: (2021)

Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Pritchett, Michael A., et al.
Publicado: (2019)

The Influence of Proteins on Fate and Biological Role of Circulating DNA
por: Tutanov, Oleg, et al.
Publicado: (2022)

Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study
por: Fu, Rui, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oorbreddm87hlcp0h051tb0mdr